174 results on '"Stirling, David I."'
Search Results
2. Clinical Pharmacokinetics of Thalidomide
3. Potent Inhibition of Cytokine Production from Intestinal Lamina Propria T Cells by Phosphodiesterase-4 Inhibitory Thalidomide Analogues
4. Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly
5. Abstract 1963: Targeting hematological malignancies with two functionally and mechanistically distinct classes of cereblon mediated protein homeostatic modulators
6. Bioavailable Dual-Protein Degraders of CK1α and Transcriptional Kinase CDK9 As Potential Therapeutics for Hematological Malignancies
7. Targeting AML: The Development of Two Functionally and Mechanistically Distinct Classes of Cereblon-Mediated Protein Homeostatic Modulators
8. Thalidomide as a novel therapeutic agent: new uses for an old product
9. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma
10. Effects of Thalidomide on Developmental, Peri- and Postnatal Function in Female New Zealand White Rabbits and Offspring
11. A Single-Dose, Two-Way Crossover, Bioequivalence Study of Dexmethylphenidate HCl with and without Food in Healthy Subjects
12. Neurobehavioral effects of racemic threo-methylphenidate and its d and l enantiomers in rats
13. The determination of a potential impurity in Thalidomide drug substance and product by HPLC with indirect UV detection
14. Thalidomide Dose Proportionality Assessment following Single Doses to Healthy Subjects
15. Safety Profile of Thalidomide after 53 Weeks of Oral Administration in Beagle Dogs
16. d-Methylphenidate is non-genotoxic in in vitro and in vivo assays
17. Sensitive and rapid method for the determination of thalidomide in human plasma and semen using solid-phase extraction and liquid chromatography–tandem mass spectrometry
18. The perinatal and postnatal toxicity of d-methylphenidate and d, l-methylphenidate in rats
19. Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma
20. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
21. Amino-substituted thalidomide analogs: Potent inhibitors of TNF-α production
22. Effect of metal-binding agents and other compounds on methane oxidation by two strains of Methylococcus capsulatus
23. Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity
24. CC-5079: A Small Molecule with MKP1, Antiangiogenic, and Antitumor Activity
25. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions
26. Lenalidomide Displays Anti-Proliferative Activity and Combination Effects with Chemotherapeutic Agents Against a Burkitt’s Lymphoma Cell Line.
27. Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma
28. Evaluation of the developmental toxicity of lenalidomide in rabbits
29. The Synthetic Compound CC-5079 Is a Potent Inhibitor of Tubulin Polymerization and Tumor Necrosis Factor-α Production with Antitumor Activity
30. Immunomodulatory Drugs (IMiDs) Increase the Production of IL-2 from Stimulated T Cells by Increasing PKC-θ Activation and Enhancing the DNA-Binding Activity of AP-1 but Not NF-κB, OCT-1, or NF-AT
31. Combination of the mTOR Inhibitor Rapamycin and Revlimid™ (CC-5013) Has Synergistic Activity in Multiple Myeloma (MM).
32. Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-α, IL-1β, and LPS-stimulated human PBMC in a partially IL-10-dependent manner
33. Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte‐macrophage differentiation of human U937 cells
34. α-Fluoro-Substituted Thalidomide Analogues.
35. Effects of thalidomide on reproductive function and early embryonic development in male and female New Zealand white rabbits
36. α-Fluoro-substituted thalidomide analogues
37. A 90-Day Oral Gavage Toxicity Study of d-Methylphenidate and d, I-Methylphenidate in Beagle Dogs
38. Potential new therapeutics for Waldenstrom's macroglobulinemia
39. The development of novel targeted therapeutics for treatment of multiple myeloma research roundtable
40. D-methylphenidate andD,L-methylphenidate are not developmental toxicants in rats and rabbits
41. Enhancement of Cytokine Production and AP-1 Transcriptional Activity in T Cells by Thalidomide-Related Immunomodulatory Drugs
42. Chiral inversion of the second generation IMiD™ CC‐4047 (ACTIMID™) in human plasma and phosphate‐buffered saline
43. Thalidomide in the treatment of leprosy
44. The perinatal and postnatal toxicity of d-methylphenidate and d,l-methylphenidate in rats
45. Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity
46. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
47. Thalidomide analogs, but not thalidomide itself, are potent inhMitors of lamina propria mononuclear cell (LPMC) TNF-A and IFN-कproduction in response to T cell stimuli
48. Thalidomide in hematologic malignancies: Future directions
49. Pharmacology of thalidomide
50. Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.